With stacked to-do list, ImCheck checks off next funding round, refueling with about $101M

A phase 2 trial ready to expand? Check. Plans for combination studies? Check. More pipeline assets to move into the clinic? Check. With all that on the to-do list, ImCheck Therapeutics has refueled with a €96 million ($101 million) funding round that featured existing investors Pfizer, Gimv and more.